Development of solid lipid nanoparticles (SLNs) of lopinavir using hot self nano-emulsification (SNE) technique

European Journal of Pharmaceutical Sciences

Volumn 48, Issue 1-2, 2013, Pages 231-239

  Negi, Jeetendra Singh ^a   Chattopadhyay, Pronobesh ^b   Sharma, Ashok Kumar ^c   Ram, Veerma ^a  

^a S Bhagwan Singh PG Institute of Bio Medical Sciences and Research   (India)

^b Defence R D Organization   (India)

^c Ministry of Health   (Eritrea)

Author keywords

Hot self nano emulsification (SNE); Lymphatic transport; Solid lipid nanoparticles (SLNs)

Indexed keywords

HOT WATER; LOPINAVIR; MACROGOL; POLOXAMER; SOLID LIPID NANOPARTICLE; STEARIC ACID;

ANIMAL EXPERIMENT; ARTICLE; ATOMIC FORCE MICROSCOPY; CHEMICAL ANALYSIS; CONTROLLED STUDY; COOLING; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG RELEASE; DRUG TRANSPORT; FEMALE; MALE; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SELF NANO EMULSIFICATION; SOLID STATE; SYNTHESIS; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION; ZETA POTENTIAL;

ANIMALS; ANTI-HIV AGENTS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; FEMALE; HOT TEMPERATURE; LOPINAVIR; MALE; MICROSCOPY, ATOMIC FORCE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; NANOTECHNOLOGY; POLOXAMER; POLYETHYLENE GLYCOLS; POWDER DIFFRACTION; RATS; RATS, WISTAR; STEARIC ACIDS; SURFACE-ACTIVE AGENTS; X-RAY DIFFRACTION;

EID: 84870338505     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.10.022     Document Type: Article

References (35)

1. S. Agarwal, D. Pal, and A.K. Mitra Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor Int. J. Pharm. 339 2007 139 147
2. M.R.A. Alex, A.J. Chacko, S. Josea, and E.B. Souto Lopinavir loaded solid lipid nanoparticles (SLNs) for intestinal lymphatic targeting Eur. J. Pharm. Sci. 42 2011 11 18
3. V. Bali, M. Ali, and J. Ali Nanocarrier for the enhanced bioavailability of a cardiovascular agent: in-vitro, pharmacodynamic, pharmacokinetic and stability assessment Int. J. Pharm. 403 2011 46 56
4. M. Boyd, V. Risovic, P. Jull, E. Choo, and K.M. Wasan A stepwise surgical procedure to investigate the lymphatic transport of lipid-based oral drug formulations: cannulation of the mesenteric and thoracic lymph ducts within the rat J. Pharmacol. Toxicol. Methods 49 2004 115 120
5. H. Chen, X. Chang, D. Du, W. Liu, J. Liu, T. Weng, Y. Yang, H. Xu, and X. Yang Podophyllotoxin loaded solid lipid nanoparticles for epidermal targeting J. Control Release. 110 2006 296 306
6. S. Cai, Q. Yang, T.R. Bagby, and M.L. Forrest Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles Adv. Drug Deliv. Rev. 63 2011 901 908
7. S. Das, and A. Choudhary Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery AAPS PharmSci. Tech. 12 2011 62 76
8. S. Das, W.K. Ng, and R.B.H. Tan Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur. J. Pharm. Sci. 47 2012 139 151
9. Debashish, D.; Rama, P.V.S.; Arbinda, S.; 2009. Process for preparing an amorphous form of (2S, 3S, 5S)-2-(2,6-Dimethylphenoxyacetyl- amino-3- hydroxyl-5-(2-(1-Tetrahydropyrimid-2-only)-3-methylbutanoyl)-amino-1,6-diphenyl hexane and product thereof (WO 2009/004653 A2).
10. Dickman, D.A.; Chemburkar, S.; Fort, J.J.; Henry, R.F.; Lechuga-Ballesteros, D.; Niu, Y.; Porter, W.; 2005. Crystalline Pharmaceuticals. US 6,864,369 B2.
11. H.J. Ensikat, M. Boese, W. Mader, W. Barthlott, and K. Koch Crystallinity of plant Epicuticular waxes: electron and X-ray diffraction studies Chem. Phys. Lipids. 144 2006 45 59
12. S. Essa, J.M. Rabanel, and P. Hildgen Characterization of rhodamine loaded PEG-g-PLA nanoparticles (NPs): effect of poly (ethyleneglycol) grafting density Int. J. Pharm. 411 2011 178 187
13. A. Kovacevic, S. Savica, G. Vuleta, R.H. Müller, and C.M. Keck Poly hydroxyl surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure Int. J. Pharm. 406 2011 163 172
14. G.N. Kumar, V.K. Jayanti, M.K. Johnson, J. Uchic, S. Thomas, R.D. Lee, B.A. Grabowski, H.L. Sham, D.J. Kempf, J.F. Denissen, K.C. Marsh, E. Sun, and S.A. Roberts Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in ratsdogs and humans Pharm. Res. 21 2004 1622 1630
15. K. Manjunath, and V. Venkateswarlu Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration J. Control Release 107 2005 215 228
16. Mascolini, Z.; 2010. What will it take to replace ritonavir as the prime pk booster? Debate ritonavir v GS9350. In: 11th International Workshop on Clinical Pharmacology of HIV Therapy Sorrento, Italy, April 7-9. < http://www.natap.org/2010/PK/PK-08.html >.
17. R.H. Muller, K. Mader, and S. Gohla Solid lipid nanoparticles (SLNs) for controlled drug delivery - a review of the state of the art Eur. J. Pharm. Biopharm. 50 2000 161 177
18. D.E. Owens, and N.A. Peppas Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles Int. J. Pharm. 307 2006 93 102
19. R. Paliwal, S. Rai, B. Vaidya, K. Khatri, A.K. Goyal, N. Mishra, A. Mehta, and S.P. Vyas Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery Nanomedicine 5 2009 184 191
20. Pharmacopoeia, 2010. The Indian Pharmacopoeia, New Delhi.
21. M. Radtke, E.B. Souto, and R.H. Müller Nanostructured lipid carriers: a novel generation of solid lipid drug carriers Pharm. Technol. Eur. 17 2005 45 50
22. R.C. Rowe, P.J. Sheskey, and M.E. Quinn Handbook of Pharmaceutical Excipients sixth ed. 2009 Pharmaceutical Press and American Pharmacist Association
23. L. Salvia-Trujillo, M.A. Rojas-Graü, R. Soliva-Fortuny, and O. Martín-Belloso Effect of processing parameters on physicochemical characteristics of microfluidized lemongrass essential oil-alginate nanoemulsions Food Hydrocolloids 30 2013 401 407
24. M. Shah, K. Chuttani, A.K. Mishra, and K. Pathak Oral solid compritol 888 ATO nanosuspension of simvastatin: optimization and biodistribution studies Drug Dev. Ind. Pharm. 37 2011 526 537
25. B. Semete, L. Booysen, L. Kalombo, B. Ramalapa, R. Hayeshi, and H.S. Swai Effects of protein binding on the biodistribution of PEGylated PLGA nanoparticles post oral administration Int. J. Pharm. 424 2012 115 120
26. P. Severino, S.C. Pinho, E.B. Souto, and M.H.A. Santana Polymorphism, crystallinity and hydrophilic-lipophilic balance of stearic acid and stearic acid-capric/caprylic triglyceride matrices for production of stable nanoparticles Colloids Surf.; B 86 2011 125 130
27. S.D. Shafran, L.D. Mashinter, and S.E. Roberts The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations HIV Med. 6 2005 421 425
28. A.C. Silva, E. González-Mira, M.L. García, M.A. Egea, J. Fonseca, R. Silva, D. Santos, E.B. Souto, and D. Ferreira Preparation, characterization and biocompatibility studies on risperidone-loaded Solid lipid nanoparticles (SLN): high pressure homogenization versus ultrasound Colloids Surf.; B 86 2011 158 165
29. S. Sinha, M. Ali, S. Baboota, A. Ahuja, A. Kumar, and J. Ali Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir AAPSPharmSciTech. 11 2010 518 527
30. L.G. Souza, E.J. Silva, A.L.L. Martins, M.F. Mota, R.C. Braga, E.M. Lima, M.C. Valadares, S.F. Taveira, and R.N. Marreto Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release Eur. J. Pharm. Biopharm. 2011 10.1016/j.ejpb.2011.02.012
31. Teixeira, A.C.T.; Garcia, A.R.; Ilharco, L.M.; Silva, A.; Fernandes, A.C.; 2010. Phase behavior of oleanolic acid, pure and mixed with stearic acid, Interactions and crystallinity-Chemistry and Physics of Lipids, 163, 655-666.
32. Trevaskis N.L.; R.M. Shanker, W.M. Charman, and C.J.H. Porter The mechanism of lymphatic access of two cholesteryl ester transfer protein inhibitors (CP524, 515 and CP532, 623) and evaluation of their impact on lymph lipoprotein profiles Pharm. Res. 27 2010 1949 1964
33. C. Vitorino, F.A. Carvalho, A.J. Almeida, J.J. Sousa, and A.A.C.C. Pais The size of solid lipid nanoparticles: an interpretation from experimental design Colloids Surf.; B 84 2011 117 130
34. T. Youssef, M. Fadel, R. Fahmy, and K. Kassab Evaluation of hypericin-loaded solid lipid nanoparticles: physicochemical properties, photostability and phototoxicity Pharm. Dev. Tech. 17 2012 177 186
35. Y. Zhao, C. Wang, A.H.L. Chow, K. Ren, T. Gong, Z. Zhang, and Y. Zheng Self-nanoemulsifying drug delivery system (SNEDDS) for oral delivery of Zedoary essential oil: formulation and bioavailability studies Int. J. Pharm. 383 2010 170 177